Scholarlink

Purpose <p>To evaluate the efficacy and safety of systemic treatment combined with radiotherapy (RT) as the first-line treatment for de novo advanced esophageal cancer (EC).</p> Methods <p>A meta-analysis was conducted, and it followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A literature search was performed systematically in PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science on February 1, 2025. The protocol of this meta-analysis was published in PROSPERO with the registration number CRD42025650118.</p> Results <p>Eight studies involving a total of 11,356 patients were finally included. Systemic treatment combined with RT improved OS (HR = 0.72, 95% CI: 0.70–0.74, <i>P</i> &lt; 0.001) and PFS (HR = 0.70, 95% CI: 0.62–0.78, <i>P</i> &lt; 0.001) compared with systemic treatment alone. The grade ≥ 3 treatment-related lymphopenia (OR = 5.52, <i>P</i> &lt; 0.001), leukopenia (OR = 1.56, <i>P</i> &lt; 0.001), and esophagitis (OR = 13.11, <i>P</i> &lt; 0.001) were more frequent in the RT-combined group; no significant differences were observed in other severe toxicities. Subgroup analysis on systemic treatment type, ESCC, and TNM stage edition also demonstrated that this RT-combined treatment could provide significant survival benefits. Exploratory analysis showed that maximal survival benefit emerged in patients who received systemic therapy, especially immunochemotherapy, combined with radical (≥ 50&#xa0;Gy) primary tumor RT.</p> Conclusions <p>By synthesizing data from both the pre-immunotherapy and immunotherapy eras involving 11,356 patients, we found that the incorporation of radical radiotherapy into first-line systemic treatment regimens improves survival outcomes while maintaining acceptable toxicity profiles in selected patients with advanced EC.Further randomized clinical trials are needed to verify our conclusions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of radiotherapy in first-line treatment for de novo advanced esophageal cancer in the era of immunochemotherapy: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月15日

查看全文
  • Hai Zeng,
  • Yan-Ling Wu,
  • Xiaofeng Wang,
  • Hui Bai,
  • Cihui Yan,
  • Wencheng Zhang,
  • Qifeng Wang

摘要

Purpose

To evaluate the efficacy and safety of systemic treatment combined with radiotherapy (RT) as the first-line treatment for de novo advanced esophageal cancer (EC).

Methods

A meta-analysis was conducted, and it followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A literature search was performed systematically in PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science on February 1, 2025. The protocol of this meta-analysis was published in PROSPERO with the registration number CRD42025650118.

Results

Eight studies involving a total of 11,356 patients were finally included. Systemic treatment combined with RT improved OS (HR = 0.72, 95% CI: 0.70–0.74, P < 0.001) and PFS (HR = 0.70, 95% CI: 0.62–0.78, P < 0.001) compared with systemic treatment alone. The grade ≥ 3 treatment-related lymphopenia (OR = 5.52, P < 0.001), leukopenia (OR = 1.56, P < 0.001), and esophagitis (OR = 13.11, P < 0.001) were more frequent in the RT-combined group; no significant differences were observed in other severe toxicities. Subgroup analysis on systemic treatment type, ESCC, and TNM stage edition also demonstrated that this RT-combined treatment could provide significant survival benefits. Exploratory analysis showed that maximal survival benefit emerged in patients who received systemic therapy, especially immunochemotherapy, combined with radical (≥ 50 Gy) primary tumor RT.

Conclusions

By synthesizing data from both the pre-immunotherapy and immunotherapy eras involving 11,356 patients, we found that the incorporation of radical radiotherapy into first-line systemic treatment regimens improves survival outcomes while maintaining acceptable toxicity profiles in selected patients with advanced EC.Further randomized clinical trials are needed to verify our conclusions.